Literature DB >> 21523363

Lipid profile in Tunisian patients with rheumatoid arthritis.

Saoussen Hassen Zrour1, Fadoua Hassine Neffeti, Nabil Sakly, Mahbouba Jguirim, Wided Korbaa, Mohamed Younes, Ismail Bejia, Mongi Touzi, Najjar Mohamed Fadel, Naceur Bergaoui.   

Abstract

This study aims to assess the prevalence of dyslipidaemia in Tunisian patients with active RA and to investigate the clinical and biological associated factors. A cross-sectional study was conducted on 92 unselected patients with active RA (77 females and 15 males, aged 49.1 ± 12.5 years) and 82 healthy subjects (68 females and 14 males, aged 50.8 ± 13.3 years). We recorded the patients' characteristics and the results of a lipid profile test (total cholesterol, TC; high-density lipoprotein cholesterol, HDL-c; low-density lipoprotein cholesterol, LDL-c; triglyceride, TG; lipoprotein (a), Lp (a); apolipoprotein A-1, apo A-1 and apolipoprotein B, apo B). In comparison to the control group, RA patients showed a higher prevalence of associated dyslipidaemia (95.7% versus 65.9% of cases, p < 0.001). Sera of patients showed higher TC (4.86 ± 1.07 versus 3.98 ± 0.73 mmol/L, p < 0.001), LDL-c (3.49 ± 0.98 versus 1.99 ± 0.62 mmol/L, p < 0.001), Lp (a) (288.04 ± 254.59 versus 187.94 ± 181.37 mmol/L, p = 0.004) and lower HDL-c (0.66 ± 0.24 versus 1.12 ± 0.3 mmol/L, p < 0.001). TC/HDL-c, LDL-c/HDL-c and non-HDL-c/HDL-c were also higher in RA patients; they were 8.24 ± 3.20 versus 3.76 ± 1.26 (p < 0.001), 5.91 ± 2.48 versus 1.92 ± 0.99 (p < 0.001) and 7.24 ± 3.20 versus 2.76 ± 1.26 (p < 0.001), respectively. Apo A-1 was correlated to Lp (a) (r = 0.291, p = 0.005). Corticoid dose was not associated to dyslipidaemia, but in multiple regression models, corticoid dose may be negatively related to some atherogenic markers, in particular non-HDL-c. Tunisian patients with markedly active RA experience substantially reduced serum HDL-c and increased TC, LDL-c and Lp (a) concentrations as well as increased TC/HDL-c, LDL-c/HDL-c and non-HDL-c/HDL-c ratios.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523363     DOI: 10.1007/s10067-011-1755-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  39 in total

1.  Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis.

Authors:  M Boers; M T Nurmohamed; C J A Doelman; L R Lard; A C Verhoeven; A E Voskuyl; T W J Huizinga; R J van de Stadt; B A C Dijkmans; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

Review 2.  Accelerated atherosclerosis in autoimmune rheumatic diseases.

Authors:  Yehuda Shoenfeld; Roberto Gerli; Andrea Doria; Eiji Matsuura; Marco Matucci Cerinic; Nicoletta Ronda; Luis J Jara; Mahmud Abu-Shakra; Pier Luigi Meroni; Yaniv Sherer
Journal:  Circulation       Date:  2005-11-22       Impact factor: 29.690

3.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

4.  Lipid profiles in untreated patients with rheumatoid arthritis.

Authors:  Y B Park; S K Lee; W K Lee; C H Suh; C W Lee; C H Lee; C H Song; J Lee
Journal:  J Rheumatol       Date:  1999-08       Impact factor: 4.666

5.  The Disease Activity Score and the EULAR response criteria.

Authors:  J Fransen; P L C M van Riel
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

6.  Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes.

Authors:  N Hyka; J M Dayer; C Modoux; T Kohno; C K Edwards; P Roux-Lombard; D Burger
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

7.  The importance of non-HDL cholesterol reporting in lipid management.

Authors:  Michael J Blaha; Roger S Blumenthal; Eliot A Brinton; Terry A Jacobson
Journal:  J Clin Lipidol       Date:  2008-06-28       Impact factor: 4.766

8.  Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.

Authors:  David W McCarey; Iain B McInnes; Rajan Madhok; Rosie Hampson; Olga Scherbakov; Ian Ford; Hilary A Capell; Naveed Sattar
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study.

Authors:  Ingiäld Hafström; Morteza Rohani; Stefan Deneberg; Margareta Wörnert; Tomas Jogestrand; Johan Frostegård
Journal:  J Rheumatol       Date:  2007-08-01       Impact factor: 4.666

10.  Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity.

Authors:  Gregorio Navarro-Cano; Inmaculada Del Rincón; Samvel Pogosian; José F Roldán; Agustín Escalante
Journal:  Arthritis Rheum       Date:  2003-09
View more
  3 in total

1.  Anti-arthritic effect of GN1, a novel synthetic analog of glucosamine, in the collagen-induced arthritis model in rats.

Authors:  Huma Jawed; Shazia Anjum; Shahid I Awan; Shabana U Simjee
Journal:  Inflamm Res       Date:  2011-08-27       Impact factor: 4.575

2.  A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis.

Authors:  I Missala; U Kassner; E Steinhagen-Thiessen
Journal:  Int J Rheumatol       Date:  2012-12-05

3.  Prevalence of Metabolic Syndrome in Treatment Naïve Rheumatoid Arthritis and Correlation With Disease Parameters.

Authors:  Purneshwar Kumar Pandey; Abhijit Swami; Tanuj Kumar Biswas; Riturag Thakuria
Journal:  Arch Rheumatol       Date:  2016-10-13       Impact factor: 1.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.